|
The proportionate benefit for small tumours is the same as for others. The HERA study included a large sample of small tumour node-negative patients.
Thus even with a post-chemo relapse in the 10% to 15% range, the gain in halving that is well worth taking given that the risks associated with hereceptin are quite low if your wife is otherwise healthy.
My wife (45) with a 1.4 cm tumour N0 had FEC(100) x 2 and Taxotere x 4 plus Herceptin for a year. So a bit more of an aggressive approach taken, largely on the basis of her relatively young age.
Good luck
John L
|
Threaded Mode